Sorry, you need to enable JavaScript to visit this website.

You are here

Recent Pfizer Press Releases

12/1/15 10:00am EST
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, President, Worldwide Research and Development, at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015 at 9:00 a.m. Eastern Standard Time.

11/25/15 8:05am EST
Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA® (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain

Pfizer Inc. (NYSE:PFE) announced today top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA® (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. The study did not meet its primary efficacy endpoint.

11/25/15 4:00am EST
Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products

  • EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC)

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the European Medicines Agency (EMA)’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug designation (ODD) for avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by the European Commission (EC), expected in December. 

11/25/15 2:00am EST
Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved a label update to expand use of XALKORI® (crizotinib) to first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). 

11/23/15 7:03am EST
Pfizer and Allergan to Combine

  • Creates a new global biopharmaceutical leader with best-in-class innovative and established businesses
  • Enhances revenue and earnings growth profile of innovative and established businesses
  • Broadens innovative pipeline with more than 100 combined mid-to-late stage programs in development
  • Transaction expected to close in the second half of 2016
  • Expected to be neutral to Pfizer’s Adjusted Diluted EPS1 in 2017, accretive beginning in calendar year 2018 and more than 10% accretive in 2019 with high-teens percentage accretion in 20202
  • Expect combined Operating Cash Flow in excess of $25 Billion beginning in 2018
  • Increased financial flexibility facilitates continued investment in the United States
  • Preserves opportunity for a potential future separation of innovative and established businesses

Pfizer Inc.

11/18/15 8:00am EST
11/18/15 7:00am EST
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

  • Breakthrough Therapy designation highlights the potential of avelumab* as a new immunotherapy for patients with metastatic Merkel cell carcinoma (MCC)
  • Metastatic MCC is a devastating disease and if approved, avelumab could potentially become the first immunotherapy to treat metastatic MCC

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen.

11/16/15 4:00am EDT
Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma

  • Trachoma is the Leading Infectious Cause of Blindness
  • More Than 100 Government, Non-Governmental and Private Sector Partners Driving Progress
  • Continued Efforts Needed to Reach 2020 Global Elimination Goal 

11/6/15 4:15pm EST
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scientific Sessions 2015

Twenty-two Abstracts to be Presented, Including New Data Analyses from the ARISTOTLE Pivotal Phase 3 Study and Real-World Data Analyses

11/5/15 8:00am EST
Pfizer Expands its Patient Assistance Program, Doubling the Income Eligibility Limit to Benefit Even More Patients Taking Pfizer Medicines

Program Offers Assistance to Insured and Uninsured Patients

In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced today that it will immediately double the allowable income level for its patient assistance program, so that even more patients in need could be eligible to receive their Pfizer medicines for free.

11/5/15 7:00am EST
Global Analysis Of Metastatic Breast Cancer Landscape Reveals Gaps In Patient Care And Support

  • First-of-its-kind Global Report Commissioned by Pfizer, Working Collaboratively with the European School of Oncology, Aims to Catalyze a Global Call-to-Action to Improve Metastatic Breast Cancer Outcomes by 2025
  • Preliminary Findings to be Presented at the Advanced Breast Cancer Third International Consensus Conference (ABC3)

Pfizer Inc., working collaboratively with the European School of Oncology (ESO), within the scope of the Advanced Breast Cancer Third International Consensus Conference (ABC3), today released the Global Status of Metastatic Breast Cancer (MBC): A 2005 – 2015 Decade Report, 

11/4/15 8:00am EST
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer

  • Trial marks second Phase III study of avelumab in non-small cell lung cancer (NSCLC) initiated by Merck KGaA, Darmstadt, Germany, and Pfizer in just over six months
  • Primary endpoint is progression-free survival in previously untreated patients with recurrent or Stage IV programmed death-ligand 1 positive (PD-L1+) NSCLC

Merck KGaA, Darmstadt, Germany, and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting.

11/2/15 8:06am EST
New Data Continue to Characterize the Safety and Efficacy of XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis

Twenty-six Pfizer scientific abstracts will be presented for the first time at the ACR/ARHP 2015 Annual Meeting

Pfizer Inc.

10/29/15 10:09am EDT
Announcement Regarding Allergan plc


10/29/15 8:00am EDT
Pfizer Announces Collaboration with GSK on Next-Generation Design of Portable, Continuous, Miniature and Modular (PCMM) Oral Solid Dose Development and Manufacturing Units

Further Enhances Pfizer’s Collaborative Effort to Help Establish PCMM as Industry Standard in Continuous Processing

Pfizer Inc. (NYSE:PFE) announced today a multi-year collaboration with GSK on the development of a next-generation equipment design, building upon Pfizer’s existing portable, continuous, miniature and modular (PCMM) prototype for oral solid dose (OSD) pharmaceutical development and manufacturing.

10/27/15 6:45am EDT

Pfizer Inc. (NYSE: PFE) reported financial results for thirdquarter 2015 and announced increases to the midpoints of its 2015 financial guidance ranges for reported revenues(1) and adjusted diluted EPS(2).

10/19/15 7:00am EDT
Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)

Pfizer Inc. today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL).

10/14/15 5:00pm EDT
Pfizer Receives Complete Response Letter from FDA for Oral XELJANZ® (tofacitinib citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis

Pfizer Inc. (NYSE: PFE) announced today it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with moderate to severe chronic plaque psoriasis.

10/13/15 8:00am EST
Pfizer and the Union for International Cancer Control Award 20 Grants Totaling $760,000 to Address the Needs of Metastatic Breast Cancer Patients Worldwide

Applications were submitted from organizations in 46 countries

This Breast Cancer Awareness Month, Pfizer Inc. and the Union for International Cancer Control (UICC) are proud to announce the recipients from the Seeding Progress and Resources for theCancer Community: Metastatic Breast Cancer Challenge (SPARC MBC Challenge), a first-of-its-kind initiative to address the unique challenges facing women with metastatic breast cancer worldwide. In total, 20 organizations from 18 countries have been selected to receive grants amounting to $760,000 (USD) in funding provided by Pfizer.

10/9/15 1:45pm EDT
Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents

Data presented for the first time at IDWeek 2015™ in San Diego

Pfizer Inc. (NYSE:PFE) announced today that researchers presented for the first time data from a randomized, controlled Phase 2 study of its meningococcal serogroup B vaccine, TRUMENBA®, coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines in adolescents.